BRPI0413439A - combinações compreendendo estaurosporinas - Google Patents

combinações compreendendo estaurosporinas

Info

Publication number
BRPI0413439A
BRPI0413439A BRPI0413439-7A BRPI0413439A BRPI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A
Authority
BR
Brazil
Prior art keywords
inhibitor
ihda
flt
malignancies
combinations
Prior art date
Application number
BRPI0413439-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Pamela Sarah Cohen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0413439A publication Critical patent/BRPI0413439A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0413439-7A 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas BRPI0413439A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49382803P 2003-08-08 2003-08-08
PCT/EP2004/008848 WO2005014004A1 (en) 2003-08-08 2004-08-06 Combinations comprising staurosporines

Publications (1)

Publication Number Publication Date
BRPI0413439A true BRPI0413439A (pt) 2006-10-17

Family

ID=34135288

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413439-7A BRPI0413439A (pt) 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas

Country Status (9)

Country Link
US (1) US20070191338A1 (enExample)
EP (2) EP1653973A1 (enExample)
JP (1) JP2007501774A (enExample)
CN (1) CN100536850C (enExample)
AU (1) AU2004262927B2 (enExample)
BR (1) BRPI0413439A (enExample)
CA (1) CA2533861A1 (enExample)
MX (1) MXPA06001524A (enExample)
WO (1) WO2005014004A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006277944A1 (en) * 2005-08-09 2007-02-15 Johannes Gutenburg-Universitat Mainz Staurosporine derivatives for treating non-small cell lung cancer
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
CA2878873C (en) 2012-07-13 2018-08-21 Turun Yliopisto A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
GB8803048D0 (en) 1988-02-10 1988-03-09 Hoffmann La Roche Substituted pyrroles
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
EP0575955B1 (en) 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
PH30300A (en) 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
JPH10501526A (ja) 1994-06-01 1998-02-10 チバ−ガイギー アクチェンゲゼルシャフト 多薬物耐性に対する作用物質としてのカルバゾール誘導体
EP0763042A1 (en) 1994-06-01 1997-03-19 Novartis AG Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711556A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
NL1003692C2 (nl) 1996-07-26 1998-01-28 Stork Protecon Langen Bv Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten.
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
DE19744676A1 (de) * 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
PT1611088E (pt) * 2003-04-07 2009-09-24 Pharmacyclics Inc Hidroxamatos como agentes terapêuticos
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Also Published As

Publication number Publication date
AU2004262927A1 (en) 2005-02-17
EP1653973A1 (en) 2006-05-10
CN1832747A (zh) 2006-09-13
CA2533861A1 (en) 2005-02-17
WO2005014004A1 (en) 2005-02-17
JP2007501774A (ja) 2007-02-01
US20070191338A1 (en) 2007-08-16
MXPA06001524A (es) 2006-05-15
AU2004262927B2 (en) 2008-05-22
CN100536850C (zh) 2009-09-09
EP2305265A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
IL260127B (en) mek inhibitors and methods of using them
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0115531A (pt) Tratamento de mucosites
CA2414967A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
DE50310516D1 (de) Fredericamycin-derivate
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0507198A (pt) derivados de bisariluréia
BR0315580A (pt) Derivados de metileno uréia
EA200500782A1 (ru) Лечение геморрагического шока
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2007147613A3 (en) Combinations comprising staurosprorines
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA202190753A1 (ru) Состав, содержащий озонированное масло, для лечения опухоли
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
NO20021437D0 (no) Fremgangsmate til forebyggelse av kolorektal kreft
NO20064753L (no) Kombinasjonsterapi
GB0316127D0 (en) Combination therapy
BR0314821A (pt) Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.